Pharmacokinetics of eplerenone after single and multiple dosing in subjects with and without renal impairment

Journal of Clinical Pharmacology

Volumn 45, Issue 7, 2005, Pages 810-821

  Ravis, William R ^a,d   Reid, Susan ^b   Sica, Domenic A ^c   Tolbert, Dwain S ^b  

^a AUBURN UNIVERSITY   (United States)

^b Pharmacia Laboratories   (United States)

^c VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d AUBURN UNIVERSITY   (United States)

Author keywords

Eplerenone; Hemodialysis; Pharmacokinetics; Renal disease; Renal impairment

Indexed keywords

CREATININE; DRUG METABOLITE; EPLERENONE; SC 70303; SC 71597; UNCLASSIFIED DRUG;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CREATININE CLEARANCE; DIZZINESS; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG HALF LIFE; DRUG METABOLISM; DRUG URINE LEVEL; FEMALE; HEADACHE; HEMODIALYSIS; HUMAN; KIDNEY CLEARANCE; KIDNEY DYSFUNCTION; KIDNEY FUNCTION; MALE; MULTIPLE DRUG DOSE; SINGLE DRUG DOSE;

ADMINISTRATION, ORAL; ADULT; AGED; AREA UNDER CURVE; CREATININE; FEMALE; HUMANS; HYPERKALEMIA; KIDNEY DISEASES; MALE; METABOLIC CLEARANCE RATE; MIDDLE AGED; RECEPTORS, ALDOSTERONE; RENAL DIALYSIS; SPIRONOLACTONE;

EID: 21044433173     PISSN: 00912700     EISSN: None     Source Type: Journal    
DOI: 10.1177/0091270005275894     Document Type: Article

References (16)

1. de Gasparo M, Joss U, Ramjone HP, et al. Three new epoxy-spironolactone derivatives: characterization in vivo and in vitro. J Pharmacol Exp Ther. 1987;240:650-656.
2. Delyani JA, Rocha R, Cook CS, et al. Eplerenone: a selective aldosterone receptor antagonist (SARA). Cardiovasc Drug Rev. 2001; 19:185-200.
3. McMahon EG. Recent studies with eplerenone, a novel selective aldosterone receptor antagonist. Curr Opin Pharmacol. 2002;1:190-196.
4. Rocha R, Funder JW. The pathophysiology of aldosterone in the cardiovascular system. Ann NY Acad Sci. 2002;970:89-100.
5. Pitt B, Zannard F, Remme WJ, et al, for the Randomized Aldactone Evaluation Study Investigators. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med. 1999;341:709-717.
6. MacFadyen RJ, Barr CS, Struthers AD. Aldosterone blockade reduces vascular collagen turnover, improves heart rate variability and reduces early morning rise in heart rate in heart failure patients. Cardiovasc Res. 1997;35:30-34.
7. Sun Y, Ramirez FJA, Weber KT. Fibrosis of stria and great vessels in response to angiotensin II or aldosterone infusion. Cardiovasc Res. 1997;35:138-147.
8. Struthers AD. Aldosterone escape during angiotensin-converting enzyme inhibitor therapy in chronic heart failure. J Card Fail. 1996; 2:47-54.
9. Straessen J, Lijnen P, Fargard R, Verschueren LJ, Amery A. Rise in plasma concentration of aldosterone during long-term angiotensin II suppression. J Endocrinol. 1981;91:457-465.
10. Krum H, Nolly H, Workman D, et al. Efficacy of eplerenone added to rennin-angiotensin blockade in hypertensive patients. Hypertension. 2002;40:117-123.
11. Weber MA. Clinical implications of aldosterone blockade. Am Heart J. 2002;144:S12-18.
12. Sica DA, Eplerenone: a new aldosterone receptor antagonist: are the FDAs restrictions appropriate? J Clin Hypertens (Greenwich). 2002;4:441-445.
13. Zhang JY, Fast DM, Breau AP. Development of and validation of a liquid chromatography-tandem mass spectrometric assay for eplerenone and its hydrolyzed metabolite in plasma. J Chromatogr B, 2003;787:333-344.
14. Zhang JY, Fast DM, Breau AP. A validated SPE-LC-MS/MS assay for eplerenone and its hydrolyzed metabolite in urine. J Pharm Biomed Anal. 2003;31:103-115.
15. Dowling TC, Briglia AE, Fink JC, et al. Characterization of hepatic cytochrome p4503 A activity in patients with end-stage renal disease. Clin Pharmacol Ther. 2003;73:427-434.
16. Leblond FA, Giroux L, Villeneuve JP, Pichette V. Decreased in vivo metabolism of drugs in chronic renal failure. Drug Metab Dispos. 2000;28:1317-1320.